- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
By 
Kyle Brasseur2023-08-16T16:22:00
Inotiv disclosed the Securities and Exchange Commission (SEC) is investigating potential violations of the Foreign Corrupt Practices Act (FCPA) by the pharmaceutical testing company regarding its importation of nonhuman primates (NHPs) from Asia.
In May, the SEC requested documents and information from Inotiv and two of its subsidiaries—Envigo Global Services and Orient BioResource Center—for the period beginning Dec. 1, 2017, to present, Inotiv revealed in a regulatory filing Friday.
The company said it is cooperating with the probe.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
A Washington state importer has been ordered by the Department of Justice to pay a $360,000 fine and hire a chief compliance officer after imported wood items the company claimed to be from Malaysia were found to be from China.
A new Foreign Corrupt Practices Act review by the Department of Justice offers an example of when stipends paid to foreign government personnel would not be considered a violation of the anti-bribery provisions of the law.
A Foreign Corrupt Practices Act review published by the Department of Justice offers further clarity around when the agency would determine expenses paid on behalf of a foreign official to be deemed “reasonable and bona fide.”
German petrochemical parts supplier Aiotec agreed to pay $14.5 million to settle allegations that it engaged in a four-year conspiracy to dismantle and ship a plastics manufacturing plant owned by a U.S. company to Iran, in violation of U.S. sanctions.
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission after self-reporting that it failed to disclose material information about two cancer drugs to investors.
The U.K. Financial Conduct Authority fined the London branch of Australian-based Macquarie Bank Limited more than 13 million pounds (U.S. $16.3 million) for “serious control failures” that allowed a trader to conceal hundreds of fictitious trades over a 20-month period.
